Abstract
In this study 125 primary lung tumours have been immunostained with a panel of 5 anti-p53 antibodies (PAb240, PAb421, PAb1801, CM-1 and C19). These antibodies recognise different epitopes over the full extent of the p53 gene. It is generally believed that immunolabelling identifies only mutant p53 proteins due to the short half life of the wild type protein. The aims of this study were to confirm earlier studies of p53 positivity in human lung tumours and to establish whether or not this bore any relationship to survival. Immunostaining was demonstrated within the nuclei of affected cells in 54% of the 125 lung tumours (59% of 78 squamous cell carcinomas, 52% of 42 adenocarcinomas and 20% of five small cell carcinomas). This confirms previous smaller studies of p53 protein expression in human lung tumours. Survival curves have been drawn for all of the cases considered together and for squamous and adenocarcinomas separately. No differences in survival between p53 positive and negative cases were seen for any group of tumours. This indicates that although p53 may be of considerable importance in the initiation of malignancy it is probably of little significance once a tumour has developed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McLaren, R., Kuzu, I., Dunnill, M. et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66, 735–738 (1992). https://doi.org/10.1038/bjc.1992.348
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.348
This article is cited by
-
Prognostic Significance of p53 Protein Expression in Early Gastric Cancer
Pathology & Oncology Research (2011)
-
The expressions and clinical significance of P53, C-erbB-2 and VEGF in non-small cell lung cancer
The Chinese-German Journal of Clinical Oncology (2008)
-
Prognostic value of p53 protein expression for patients with gastric cancer – a multivariate analysis
British Journal of Cancer (1999)
-
Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies
Journal of Cancer Research and Clinical Oncology (1997)